Invesaro

Stocks Comparison

Cadre vs Edwards Lifesciences: revenue, profit, margins and growth compared

Cadre brought in $610.3M of revenue in fiscal 2025, Edwards Lifesciences $6.1B in fiscal 2025. Revenue changed by +7.5% at Cadre and +11.5% at Edwards Lifesciences on the year before, so Edwards Lifesciences grew faster. Cadre kept 7.2% of its revenue as net profit, Edwards Lifesciences 17.7%. Free cash flow was $56.8M at Cadre and $1.3B at Edwards Lifesciences.

Side by side, latest fiscal year

CDREEW
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$610.3M$6.1B
Revenue growth+7.5%+11.5%
Net income$44.1M$1.1B
Net margin7.2%17.7%
Free cash flow$56.8M$1.3B
Free cash flow margin9.3%22.0%
Earnings per share (diluted)$1.02$1.83
Cash$122.9M$2.9B
Debt$307.3M$598.3M
Price to earnings25.947.1
Market value$1.1B$49.7B
Dividend yield0.36%n/a
Rank by revenue in sector#179 of 523 · Health care#54 of 523 · Health care

Over the years

Revenue
CDRE FY2021: $404.6MCDRE FY2021: $427.3MCDRE FY2022: $457.8MCDRE FY2023: $482.5MCDRE FY2024: $567.6MCDRE FY2025: $610.3MEW FY2018: $3.7BEW FY2019: $4.3BEW FY2020: $4.4BEW FY2021: $5.2BEW FY2022: $4.5BEW FY2023: $5BEW FY2024: $5.4BEW FY2025: $6.1BFY18FY19FY20FY21FY22FY23FY24FY25
CDRE $610.3MEW $6.1B
Net income
CDRE FY2021: $38.5MCDRE FY2021: $12.7MCDRE FY2022: $5.8MCDRE FY2023: $38.6MCDRE FY2024: $36.1MCDRE FY2025: $44.1MEW FY2018: $722.2MEW FY2019: $1BEW FY2020: $823.4MEW FY2021: $1.5BEW FY2022: $1.5BEW FY2023: $1.4BEW FY2024: $4.2BEW FY2025: $1.1BFY18FY19FY20FY21FY22FY23FY24FY25
CDRE $44.1MEW $1.1B
Net margin
CDRE FY2021: 9.5%CDRE FY2021: 3.0%CDRE FY2022: 1.3%CDRE FY2023: 8.0%CDRE FY2024: 6.4%CDRE FY2025: 7.2%EW FY2018: 19.4%EW FY2019: 24.1%EW FY2020: 18.8%EW FY2021: 28.7%EW FY2022: 34.1%EW FY2023: 28.0%EW FY2024: 76.7%EW FY2025: 17.7%FY18FY19FY20FY21FY22FY23FY24FY25
CDRE 7.2%EW 17.7%
Revenue growth
CDRE FY2021: +5.6%CDRE FY2022: +7.1%CDRE FY2023: +5.4%CDRE FY2024: +17.6%CDRE FY2025: +7.5%EW FY2019: +16.8%EW FY2020: +0.9%EW FY2021: +19.3%EW FY2022: -14.7%EW FY2023: +12.2%EW FY2024: +8.6%EW FY2025: +11.5%FY19FY20FY21FY22FY23FY24FY25
CDRE +7.5%EW +11.5%
Free cash flow
CDRE FY2021: $40.7MCDRE FY2021: $37.3MCDRE FY2022: $41.9MCDRE FY2023: $66.5MCDRE FY2024: $26.1MCDRE FY2025: $56.8MEW FY2018: $688MEW FY2019: $928.5MEW FY2020: $647.3MEW FY2021: $1.4BEW FY2022: $973.6MEW FY2023: $642.8MEW FY2024: $289.9MEW FY2025: $1.3BFY18FY19FY20FY21FY22FY23FY24FY25
CDRE $56.8MEW $1.3B

Fiscal years as each company reports them; the two may end in different months.

Questions about Cadre and Edwards Lifesciences

Which is bigger by revenue, Cadre or Edwards Lifesciences?

Edwards Lifesciences is bigger by revenue: $6.1B in fiscal 2025, against $610.3M for Cadre in fiscal 2025.

Which keeps more of its revenue as profit, Cadre or Edwards Lifesciences?

Cadre had a net margin of 7.2% in fiscal 2025; Edwards Lifesciences had 17.7% in fiscal 2025.

Which grew revenue faster, Cadre or Edwards Lifesciences?

In their latest fiscal years revenue changed by +7.5% at Cadre and +11.5% at Edwards Lifesciences.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies